FTO in cancer: functions, molecular mechanisms, and therapeutic implications.

Yangchan Li, Rui Su, Xiaolan Deng, Yong Chen, Jianjun Chen

Journal: Trends in cancer 2022;8(7):598-614

PMID: 35346615

Abstract

N-methyladenosine (mA) is the most abundant internal modification in mRNA that affects RNA processing, stability, and translation. Discovered as the first RNA mA demethylase, the fat mass and obesity-associated protein (FTO) is frequently dysregulated and plays important roles in various types of cancers. Targeting FTO holds promising therapeutic significance via suppressing tumor growth, potentiating immunotherapy, and attenuating drug resistance. Here, we review recent advances in our understanding of the functions and underlying molecular mechanisms of FTO in tumor development, cancer stem cell (CSC) self-renewal, microenvironment regulation, immunity, and metabolism and discuss the therapeutic potential of targeting FTO for cancer treatment.

Copyright © 2022 Elsevier Inc. All rights reserved.

Address: Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.; Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA. Electronic address: [email protected].; Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.; Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA. Electronic address: [email protected].

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.